News
-
-
PRESS RELEASE
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Heidelberg Pharma granted orphan drug designation by FDA for its ATAC candidate HDP-101, targeting multiple myeloma. The designation provides significant benefits for the development and potential marketing of the drug -
-
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform -
-
PRESS RELEASE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway -
-
PRESS RELEASE
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens -
-
PRESS RELEASE
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Heidelberg Pharma to present first efficacy data on HDP-101 and data from proprietary ADC technology platform at AACR Meeting 2024. Details of ATAC and ADC-based cancer therapies
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DuJour Media Jason Binn Celebrates Successful 12th Anniversary Cover Party with Star-Studded After-Party and Record Turnout
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
-
Meyer Burger makes significant progress in relocating its core business to the USA
-
BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024. Detailed information per transaction
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024